itolizumab (Idogen)

ItolDC-028 (formerly referred to as itolizumab by its developer, Idogen) is an autologous tolerogenic dendritic cell therapy that was developed for the treatment of severe hemophilia A, specifically for patients who have developed neutralizing antibodies (inhibitors) against Factor VIII (FVIII). The therapeutic approach involves isolating a patient's own monocytes, differentiating them into dendritic cells ex vivo, and loading them with recombinant FVIII in the presence of a tolerance-inducing compound. These modified cells are then re-infused into the patient with the aim of inducing immunological tolerance to FVIII, thereby suppressing the inhibitor response and restoring the efficacy of standard FVIII replacement therapy. Although the program reached Phase 1/2a clinical testing (NCT04307914), development was halted following Idogen's liquidation in 2023. It is important to note that this cell therapy is entirely distinct from the CD6-targeting monoclonal antibody also named itolizumab (Alzumab).

Other names

Itolizumab